Lucid Diagnostics Inc

Lucid Diagnostics insider buys signal confidence amid a steep fall—discover how Dennis’s 245k‑share purchase reflects potential upside if the esophageal diagnostic platform advances.

Lucid Diagnostics insider holding signals long‑term confidence, fresh capital, and a strong, value‑based reimbursement strategy for its ctDNA esophageal cancer test.

Lucid Diagnostics insider stake rise fuels optimism as breakthrough esophageal brush‑biopsy tech shows 92% sensitivity, 88% specificity, and strong FDA support, hinting at future growth.

Lucid Diagnostics insider buying spikes amid VA contract win—an insider confidence boost, but negative earnings and low valuations highlight the need for solid revenue and reimbursement wins to create lasting value.